Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

REPLATINUM Phase III randomized study: RRx-001 + platinum doublet versus platinum doublet in third-line small cell lung cancer.

Oronsky B, Reid TR, Larson C, Caroen S, Quinn M, Burbano E, Varner G, Thilagar B, Brown B, Coyle A, Ferry L, Abrouk N, Oronsky A, Scribner CL, Carter CA.

Future Oncol. 2019 Oct;15(30):3427-3433. doi: 10.2217/fon-2019-0317. Epub 2019 Sep 11.

PMID:
31509028
2.

Upending this country's approach to health care.

Reid TR.

J Fam Pract. 2018 Dec;67(12):744-745. No abstract available.

PMID:
30566116
3.

A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs).

Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter CA, Reid TR.

Oncoimmunology. 2018 Jul 23;7(9):e1478648. doi: 10.1080/2162402X.2018.1478648. eCollection 2018. Review.

4.

Case Series: Abscopal Benefit of Surgery in 3 Immunotherapy-Treated Patients With Unresectable Cancer.

Oronsky B, Larson C, Reid TR, Carter CA.

J Investig Med High Impact Case Rep. 2018 Jul 6;6:2324709618786319. doi: 10.1177/2324709618786319. eCollection 2018 Jan-Dec.

5.

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

Oronsky B, Reid TR, Oronsky A, Caroen S, Carter CA, Cabrales P.

Oncotarget. 2018 May 4;9(34):23439-23442. doi: 10.18632/oncotarget.25211. eCollection 2018 May 4.

6.

Navigating the "No Man's Land" of TKI-Failed EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): A Review.

Oronsky B, Ma P, Reid TR, Cabrales P, Lybeck M, Oronsky A, Oronsky N, Carter CA.

Neoplasia. 2018 Jan;20(1):92-98. doi: 10.1016/j.neo.2017.11.001. Epub 2017 Dec 8. Review.

7.

No patient left behind: The promise of immune priming with epigenetic agents.

Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR.

Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Review.

8.

What's New in SCLC? A Review.

Oronsky B, Reid TR, Oronsky A, Carter CA.

Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6. Review.

9.

Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management.

Oronsky B, Caroen S, Oronsky A, Dobalian VE, Oronsky N, Lybeck M, Reid TR, Carter CA.

Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20. Review.

10.

RRx-001 Priming of PD-1 Inhibition in the Treatment of Small Cell Carcinoma of the Vagina: A Rare Gynecological Tumor.

Brzezniak C, Oronsky B, Trepel J, Summers TA Jr, Cabrales P, Lee MJ, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck HE, Brown JF, Reid TR, Carter CA.

Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.

11.

RRx-001 protects against cisplatin-induced toxicities.

Oronsky B, Reid TR, Larson C, Carter CA, Brzezniak CE, Oronsky A, Cabrales P.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1671-1677. doi: 10.1007/s00432-017-2416-4. Epub 2017 Apr 17.

PMID:
28417195
12.

RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.

Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA.

Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Review. Erratum in: Expert Opin Investig Drugs. 2017 Feb;26(2):261. Carterg, Corey A [corrected to Carter, Corey A].

13.

Conversion of Platinum-Etoposide-Resistant to Sensitive SCLC after Treatment with the Epi-Immunotherapeutic RRx-001: A Case Report.

Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim MM, Brown JF, Reid TR, Larson C, Oronsky A, Day R, Degesys A, Carter CA.

Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.

PMID:
27855386
14.

A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001.

Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA.

Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.

15.

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets.

Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C.

Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.

16.

Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.

Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A.

Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032. Review.

17.

Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001.

Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C.

Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. eCollection 2016 Jan-Apr.

18.

Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance.

Oronsky B, Carter CA, Reid TR, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P.

Neoplasia. 2015 Sep;17(9):716-722. doi: 10.1016/j.neo.2015.09.001. Review.

19.

Going viral: a review of replication-selective oncolytic adenoviruses.

Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR.

Oncotarget. 2015 Aug 21;6(24):19976-89. Review.

20.

Episensitization: Defying Time's Arrow.

Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR.

Front Oncol. 2015 Jun 11;5:134. doi: 10.3389/fonc.2015.00134. eCollection 2015. Review.

21.

Phase I study of everolimus, cetuximab and irinotecan as second-line therapy in metastatic colorectal cancer.

Hecht JR, Reid TR, Garrett CR, Beck JT, Davidson SJ, Mackenzie MJ, Brandt U, Rizvi S, Sharma S.

Anticancer Res. 2015 Mar;35(3):1567-73.

PMID:
25750312
22.

Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Mendez N, Herrera V, Zhang L, Hedjran F, Feuer R, Blair SL, Trogler WC, Reid TR, Kummel AC.

Biomaterials. 2014 Nov;35(35):9554-61. doi: 10.1016/j.biomaterials.2014.08.010. Epub 2014 Aug 22.

23.

Intermittent dosing of axitinib combined with chemotherapy is supported by (18)FLT-PET in gastrointestinal tumours.

Hoh CK, Burris HA 3rd, Bendell JC, Tarazi J, Rosbrook B, Kim S, Infante JR, Reid TR.

Br J Cancer. 2014 Feb 18;110(4):875-81. doi: 10.1038/bjc.2013.806. Epub 2014 Jan 14.

24.

Oncolytic virotherapy.

Sze DY, Reid TR, Rose SC.

J Vasc Interv Radiol. 2013 Aug;24(8):1115-22. doi: 10.1016/j.jvir.2013.05.040. Review.

PMID:
23885911
25.

Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.

Infante JR, Reid TR, Cohn AL, Edenfield WJ, Cescon TP, Hamm JT, Malik IA, Rado TA, McGee PJ, Richards DA, Tarazi J, Rosbrook B, Kim S, Cartwright TH.

Cancer. 2013 Jul 15;119(14):2555-63. doi: 10.1002/cncr.28112. Epub 2013 Apr 19.

26.

Program, policy, and price interventions for tobacco control: quantifying the return on investment of a state tobacco control program.

Dilley JA, Harris JR, Boysun MJ, Reid TR.

Am J Public Health. 2012 Feb;102(2):e22-8. doi: 10.2105/AJPH.2011.300506. Epub 2011 Dec 15.

27.

Response to intra-arterial oncolytic virotherapy with the herpes virus NV1020 evaluated by [18F]fluorodeoxyglucose positron emission tomography and computed tomography.

Sze DY, Iagaru AH, Gambhir SS, De Haan HA, Reid TR.

Hum Gene Ther. 2012 Jan;23(1):91-7. doi: 10.1089/hum.2011.141. Epub 2011 Oct 14.

PMID:
21895536
28.

Promoting tobacco cessation via the workplace: opportunities for improvement.

Hughes MC, Yette EM, Hannon PA, Harris JR, Tran NM, Reid TR.

Tob Control. 2011 Jul;20(4):305-8. doi: 10.1136/tc.2010.041038. Epub 2011 Mar 3.

PMID:
21377998
29.

Universal coverage. 'They did it. We could do it'.

Reid TR.

Health Prog. 2010 Nov-Dec;91(6):55-9. No abstract available.

PMID:
21140849
30.

Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver.

Geevarghese SK, Geller DA, de Haan HA, Hörer M, Knoll AE, Mescheder A, Nemunaitis J, Reid TR, Sze DY, Tanabe KK, Tawfik H.

Hum Gene Ther. 2010 Sep;21(9):1119-28. doi: 10.1089/hum.2010.020.

31.
32.

Resection of hepatic metastasis after 5-fluorouracil and cofactor for colon cancer.

Costantini CL, Reid TR, Bouvet M.

Hepatogastroenterology. 2009 May-Jun;56(91-92):645-9.

PMID:
19621672
33.

Antimicrobial activities of jadomycin B and structurally related analogues.

Jakeman DL, Bandi S, Graham CL, Reid TR, Wentzell JR, Douglas SE.

Antimicrob Agents Chemother. 2009 Mar;53(3):1245-7. doi: 10.1128/AAC.00801-08. Epub 2008 Dec 15.

34.

Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.

Trivedi M, Budihardjo I, Loureiro K, Reid TR, Ma JD.

Future Oncol. 2008 Aug;4(4):483-500. doi: 10.2217/14796694.4.4.483. Review.

PMID:
18684060
35.

Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.

Saylor PJ, Reid TR.

J Clin Oncol. 2007 Aug 10;25(23):3544-6. No abstract available.

PMID:
17687160
36.

Stereochemical integrity of oxazolone ring-containing jadomycins.

Borissow CN, Graham CL, Syvitski RT, Reid TR, Blay J, Jakeman DL.

Chembiochem. 2007 Jul 9;8(10):1198-203.

PMID:
17570722
37.

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.

Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR.

Cancer Gene Ther. 2007 Feb;14(2):139-50. Epub 2006 Dec 1.

PMID:
17139321
38.

Substrate flexibility of a 2,6-dideoxyglycosyltransferase.

Jakeman DL, Borissow CN, Graham CL, Timmons SC, Reid TR, Syvitski RT.

Chem Commun (Camb). 2006 Sep 21;(35):3738-40. Epub 2006 Aug 2.

PMID:
17047829
39.

Novel and expanded jadomycins incorporating non-proteogenic amino acids.

Jakeman DL, Graham CL, Reid TR.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5280-3. Epub 2005 Sep 26.

PMID:
16185863
40.

Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin.

Reid TR, Freeman S, Post L, McCormick F, Sze DY.

Cancer Gene Ther. 2005 Aug;12(8):673-81.

PMID:
15803147
41.

Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival.

Sze DY, Freeman SM, Slonim SM, Samuels SL, Andrews JC, Hicks M, Ahrar K, Gupta S, Reid TR.

J Vasc Interv Radiol. 2003 Mar;14(3):279-90.

PMID:
12631632
42.

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM.

Clin Cancer Res. 2003 Feb;9(2):555-61.

43.

Developments in medical oncology and their implications for interventional radiology.

Reid TR, Sze DY.

Tech Vasc Interv Radiol. 2002 Sep;5(3):177-81. Review.

PMID:
12524649
44.

A novel method to control severe upper GI bleeding from metastatic cancer with a hemostatic sealant: the CoStasis surgical hemostat.

Milkes DE, Friedland S, Lin OS, Reid TR, Soetikno RM.

Gastrointest Endosc. 2002 May;55(6):735-40. No abstract available.

PMID:
11979262
45.
46.

Resistance to interferon-alpha in a mouse B-cell lymphoma involves DNA methylation.

Reid TR, Merigan TC, Basham TY.

J Interferon Res. 1992 Apr;12(2):131-7.

PMID:
1374455
48.

Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma.

Reid TR, Race ER, Wolff BH, Friedman RM, Merigan TC, Basham TY.

Cancer Res. 1989 Aug 1;49(15):4163-9.

49.

Evidence for two mechanisms by which tumor necrosis factor kills cells.

Reid TR, Torti FM, Ringold GM.

J Biol Chem. 1989 Mar 15;264(8):4583-9.

50.

Synergistic antitumor activity with IFN and monoclonal anti-idiotype for murine B cell lymphoma. Mechanism of action.

Basham TY, Race ER, Campbell MJ, Reid TR, Levy R, Merigan TC.

J Immunol. 1988 Oct 15;141(8):2855-60.

PMID:
2971732

Supplemental Content

Support Center